Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Multiple Myeloma 1Lymphoma, Mantle-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Hairy Cell 1

Interventions

Rituximab 14Bortezomib 9Peripheral Blood Stem Cell Transplantation 6fludarabine phosphate 5Filgrastim 5temsirolimus 4tanespimycin 4alvocidib 4Magnetic Resonance Spectroscopy 4Indium 4Cyclophosphamide 4ibritumomab tiuxetan 3Vorinostat 3Sirolimus 3Carboplatin 3sargramostim 2oblimersen 2ibrutinib 2belinostat 2Radiotherapy 2Pharmacogenomic Testing 2Methotrexate 2MK 2206 2Lenalidomide 2Interleukin-12 Subunit p35 2Interferon-alpha 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Cyclosporine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Waldenstrom Macroglobulinemia × ON 01910 × Clear all
NCT00861510 2019-12-03

A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
16 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Hairy Cell, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡